069620.KS KSC
Daewoong pharmaceutical Co.,Ltd
1W: +2.6%
1M: -14.0%
3M: -7.9%
YTD: -39.1%
1Y: -18.7%
3Y: +13.3%
5Y: -37.1%
₩109,000.00 ($81.19)
-600.00 (-0.55%)
Weekly Expected Move ±4.8%
₩98556
₩103778
₩109000
₩114222
₩119444
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
ETF Exposure
Cash Flow Trends
Operating Cash Flow
$149.2B
+189.8% ▲
5Y CAGR: +8.1%
Capital Expenditures
$191.5B
+16.4% ▲
5Y CAGR: +26.3%
Free Cash Flow
-$42.3B
+76.2% ▲
Dividends Paid
$8.1B
-4.3% ▼
Buybacks
$0
+0.0% ▲
Net Change in Cash
$66.0B
+871.3% ▲
Cash Flow Composition
Year-over-Year Growth
View Full Cash Flow Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| — Operating Activities — | |||||
| Net Income | $30.3B | $39.2B | $121.7B | $23.3B | $195.9B |
| Depreciation & Amort. | $40.9B | $39.7B | $42.7B | $49.0B | $50.3B |
| Stock-Based Comp. | $2.0B | $1.8B | $253M | $545M | $0 |
| Change in Working Capital | -$29.9B | $31.6B | -$25.7B | -$82.8B | -$74.5B |
| Other Non-Cash Items | $3.9B | $5.9B | -$3.0B | $61.4B | -$22.4B |
| Operating Cash Flow | $40.0B | $118.2B | $136.0B | $51.5B | $149.2B |
| — Investing Activities — | |||||
| Capital Expenditures | -$74.8B | -$113.3B | -$109.3B | -$155.1B | -$241.4B |
| Acquisitions (Net) | -$572M | -$9.0B | -$4.3B | $1.7B | $121M |
| Investment Purchases | -$319.0B | -$23.6B | -$17.7B | -$34.3B | -$17.3B |
| Investment Sales | $306.4B | $30.6B | $3.1B | $167M | $13.4B |
| Other Investing | $331M | $8.4B | -$37.4B | -$77.9B | -$2.2B |
| Investing Cash Flow | -$87.7B | -$106.9B | -$165.6B | -$265.5B | -$247.4B |
| — Financing Activities — | |||||
| Net Debt Issuance | -$632M | $125M | $148M | $205.9B | $175.1B |
| Stock Repurchased | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | -$6.5B | -$6.6B | -$6.6B | -$7.7B | -$8.1B |
| Other Financing | $17.1B | $22.0B | -$4.2B | $2.4B | -$2.3B |
| Financing Cash Flow | $50.2B | $15.5B | $39.2B | $200.6B | $164.7B |
| Net Change in Cash | $3.6B | $27.0B | $8.6B | -$8.6B | $66.0B |
| Cash End of Period | $75.9B | $103.0B | $111.5B | $103.0B | $168.9B |
| Free Cash Flow | -$34.8B | $4.9B | $13.9B | -$177.5B | -$42.3B |